Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.

The marked efficacy of spesolimab in GPP opens a new era of highly effective, scientifically-rational and evidence-based treatment for this orphan disease, and has implications for other diseases in which interleukin 36 signaling is involved.